Search for: "In re: Accutane Litigation" Results 41 - 60 of 61
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Apr 2020, 5:01 am by Schachtman
In granting a Rule 702 motion to exclude the expert witnesses who relied upon a DPA, the trial judge rejected the probativeness of DPAs, based upon the FDA’s rejection of such analyses for anything other than signal detection.[3] In the Accutane litigation, statistician David Madigan attempted to support his fatally weak causation opinion with a DPA for Crohn’s disease and Accutane adverse event reports. [read post]
2 Apr 2020, 5:16 am by Schachtman
Zambelli-Weiner’s Litigation Road Map In a world where social justice warriors complain about organizations such as Exponent, for its litigation support of defense efforts, the revelation that Zambelli-Weiner was helping to quarterback the plaintiffs’ offense deserves greater recognition. [read post]
28 Dec 2012, 1:57 pm by Bexis
                  In re Pelvic Mesh/Gynecare Litigation, 43 A.3d 1211 (N.J. [read post]
4 Nov 2018, 10:56 am by Schachtman
Pl., Feb. 10, 2016) (Bernstein, J.). 2 Institute of Medicine of the National Academies, Asbestos: Selected Health Effects (2006). 3 In re Accutane Litig., ___ N.J. ___, ___ A.3d ___, 2018 WL 3636867 (2018); see “N.J. [read post]
5 Apr 2015, 7:50 pm by Schachtman
Pa. 2014) (excluding perinatal epidemiologist, Anick Bérard, for biased cherry picking of data points); In re Accutane, No. 271(MCL), 2015 WL 753674, 2015 BL 59277 (N.J.Super. [read post]
23 Jan 2020, 10:37 pm by Schachtman
Singh abandoned his own interpretative principle to suit the litigation needs of the case. [read post]
31 Dec 2015, 5:12 am
  Full disclosure:  Reed Smith is involved in Caplinger, so consider this entry a non-RS post.In re Celexa & Lexapro Marketing & Sales Practices Litigation, 779 F.3d 34 (1st Cir. 2015). [read post]
27 Mar 2007, 11:29 pm
Evid. 502 - an update (5/30/07)"Relatedness" assessments (In re Accutane) (5/28/07)Preemption lite (5/24/07)Riegel v. [read post]
13 Jun 2008, 12:12 pm
We can't think of any such case, and that would take more research than we're inclined to do right now. [read post]
7 Jun 2007, 10:52 am
Sandoz Pharmaceuticals Corp., 289 F.3d 1193, 1211 (10th Cir. 2002) (ADEs "contain only limited information" and are "unreliable evidence of causation"); In re: Accutane Products Liability Litigation, 2007 WL 1288354, at *3 (M.D. [read post]
21 Feb 2014, 8:53 am
”  In re Fosamax Products Liability Litigation, 2013 WL 174416, at *1 (S.D.N.Y. [read post]
14 Aug 2011, 9:11 am by Schachtman
  Merrell challenged Swan’s unpublished, non-peer-reviewed re-analyses as not “generally accepted” under the Frye test. [read post]
22 May 2021, 12:04 pm by admin
The gravamen of the defense’s appeal was that these expert witnesses had failed to support their opinions and that the trial judge had misapplied the established judicial gatekeeping procedures required by the New Jersey Supreme Court, in In re Accutane Litigation, 234 N.J. 340 (2018). [read post]
16 Sep 2016, 2:02 pm by Schachtman
  Judge Johnson first distinguished himself in In re Accutane, No. 271(MCL), 2015 WL 753674, 2015 BL 59277 (N.J.Super. [read post]
1 Feb 2013, 9:42 am by Bexis
Aug. 20, 2012) (“federal law requires a generic drug to be of the same design as its brand name counterpart”); In re: Accutane Products Liability Litigation, 2012 WL 3194952, at *2 (M.D. [read post]
12 Sep 2008, 10:24 am
Fla. 1996), aff’d, 158 F. 3d 588 (11th Cir. 1998); In re Accutane Products Liability Litig., 511 F. [read post]
12 Dec 2021, 2:22 pm by admin
Litig., 858 F.3d 787, 793 (3d Cir. 2017) (affirming exclusion of causation expert witness) Magistrini v. [read post]
9 Nov 2015, 7:09 am
 For instance, notwithstanding its eventual total victory, the maker of Accutane was forced to withdraw that drug from the market in 2009 due to the litigation cost of defending claims over purported side effects that either didn’t exist or were adequately warned about. [read post]
10 Feb 2023, 4:44 am by admin
Putting aside the idiosyncratic chapter by the late Professor Berger, most of the third edition of the Reference Manual presented guidance on many important issues. [read post]